Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES
13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
(Amendment No. 7)*
Fibrocell Science, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
315721100
(CUSIP Number)
December 31, 2009
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13G
CUSIP NO. 315721100
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities
Only)
1
Michael A. Roth and Brian J. Stark, as joint filers
pursuant to Rule 13d-1(k).
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) |X|
(b) |_|
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
NUMBER OF SOLE VOTING POWER
5
SHARES 0
BENEFICIALLY SHARED VOTING POWER
6
OWNED BY EACH Common Stock equal to less than 5%
REPORTING SOLE DISPOSITIVE POWER
7
0
PERSON WITH
SHARED DISPOSITIVE POWER
8
Common Stock equal to less than 5%
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
9
Common Stock equal to less than 5%
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES [__]
10
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11
Less than 5%
TYPE OF REPORTING PERSON
12
IN
CUSIP NO. 315721100
Item 1(a). Name of Issuer:
Fibrocell Science, Inc.(the "Issuer").
Item 1(b). Address of Issuer's Principal Executive Offices:
405 Eagleview Boulevard
Exton, Pennsylvania 19341
Items 2(a),
(b) and (c). Name of Persons Filing, Address of Principal Business Office
and Citizenship:
This Amendment No. 7 to Schedule 13G is being filed on behalf
of Michael A. Roth and Brian J. Stark, as joint filers
(collectively, the "Reporting Persons").
The Reporting Persons have entered into a Joint Filing
Agreement, a copy of which is filed with this Amendment No. 7
to Schedule 13G as Exhibit 1, pursuant to which the Reporting
Persons have agreed to file this Schedule 13G jointly in
accordance with the provisions of Rule 13d-1(k) of the
Securities Exchange Act of 1934, as amended (the "Exchange
Act").
The principal business office of the Reporting Persons is
3600 South Lake Drive, St. Francis, WI 53235. The Reporting
Persons are citizens of the United States of America.
Item 2(d). Title of Class of Securities:
Common Stock, par value $0.001 per share (the "Common Stock")
Item 2(e). CUSIP Number:
315721100
Item 3. Not applicable.
Item 4. Ownership.
(a) Amount beneficially owned:
Common Stock equal to less than 5%
(b) Percent of class: Less than 5%
(c) Number of shares to which such person has:
(i) Sole power to vote or direct the vote: 0
(ii) Shared power to vote or direct the vote: Common
Stock equal to less than 5%
(iii) Sole power to dispose or to direct the disposition
of: 0
(iv) Shared power to dispose of or direct the disposition
of: Common Stock equal to less than 5%
Item 5. Ownership of Five Percent or Less of a Class.
This statement is being filed to report the fact that as of
the date hereof the reporting persons have ceased to be the
beneficial owner of more than five percent of the class of
of securities, check the following [X]
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported By the Parent Holding
Company.
Not applicable
Item 8. Identification and Classification of Members of the Group.
Not applicable
CUSIP NO. 315721100
Item 9. Notice of Dissolution of a Group.
Not applicable
Item 10. Certification.
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the
effect of changing or influencing the control of the issuer
of the securities and were not acquired and are not held in
connection with or as a participant in any transaction
having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: February 16, 2010
/s/ Michael A. Roth
Michael A. Roth
/s/ Brian J. Stark
Brian J. Stark
CUSIP NO. 315721100
Exhibit 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934,
as amended, the undersigned agree to the joint filing on behalf of each of them
of a statement on Schedule 13G (including amendments thereto) with respect to
certain shares of Common Stock of Fibrocell Science, Inc. and further agree that
this Joint Filing Agreement shall be included as an exhibit to such joint
filings.
The undersigned further agree that each party hereto is responsible for the
timely filing of such Schedule 13G and any amendments thereto, and for the
completeness and accuracy of the information concerning such party contained
therein; provided, however, that no party is responsible for the completeness or
accuracy of the information concerning any other party making the filing, unless
such party knows or has reason to believe that such information is inaccurate.
IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement
on February 16, 2010.
/s/ Michael A. Roth
Michael A. Roth
/s/ Brian J. Stark
Brian J. Stark